News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
PrEP
Tests of online PrEP purchases by London clinic find no fakes, and adequate drug levels

A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate

Published
26 October 2016
By
Gus Cairns
Side-effects
Doctors in Netherlands observe higher than expected dolutegravir treatment discontinuation rate

Almost one in seven people in a Dutch clinic population stopped treatment with the HIV integrase inhibitor dolutegravir because of side-effects, investigators from the Netherlands report in

Published
13 October 2016
By
Michael Carter
PrEP
Evidence that “on-demand” PrEP taken before and after sex can prevent HIV

How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day?

Published
12 September 2016
From
BETA blog
Drug interactions and pharmacokinetics
University HIV smartphone app receives international award

A smartphone application developed by the University of Liverpool to help healthcare professionals to safely prescribe medications for HIV patients has won an international award.

Published
01 September 2016
From
University of Liverpool press release
Hepatitis C treatment
Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study

The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes in people with HIV/HCV co-infection and was safe and well

Published
21 July 2016
By
Liz Highleyman
Drug interactions and pharmacokinetics
Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals

Sofosbuvir/velpatasvir, a forthcoming combination that effectively treats all hepatitis C virus (HCV) genotypes, can be safely used with most boosted antiretrovirals for people with HIV and HCV

Published
14 March 2016
By
Liz Highleyman
Transgender people
Transgender people are at high risk for HIV, but too little is known about prevention and treatment for this population

Transgender women have among the highest rates of HIV infection but little is known about HIV prevalence among trans men, Tonia Poteat of Johns Hopkins Bloomberg School

Published
11 March 2016
By
Liz Highleyman
PrEP
Women need more of the HIV drug Truvada than men to prevent infection

Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers the University of North Carolina at Chapel Hill.

Published
04 March 2016
From
Eurekalert Medicine & Health
PrEP
Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016

A case report of a man in Toronto who became infected with a multi-drug-resistant strain of HIV despite apparently very consistent adherence to PrEP was presented at

Published
25 February 2016
By
Gus Cairns
The search for a cure
Study: HIV can hide and grow in 'sanctuaries' in body after it's undetectable in blood

The latest study appears to show a different type of "sanctuary," as the researchers called it, harboring cells with low levels of HIV replication that move into the blood. This suggests that virus growth could occur in a place where drug concentrations are very low.

Published
28 January 2016
From
Washington Post
← Prev1...34567...24Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.